EU pharma sector inquiry -- the IPI response

The Intellectual Property Institute has prepared a paper for the EU Commission in response to the DG Competition Inquiry into the pharmaceutical sector (on which see IPKat posts here and here). Since responses have not yet apparently been posted on the Commission website, the IPKat is taking the liberty of pinning the IPI's response here. This response reflects the efforts of Duncan Curley and Steve Smith, who had to work to a very tight time framework and who, all things considered, have done a pretty good job.

Right: the IPKat has his own opinion about pharmaceutical products, but for once he's keeping his mouth shut.

STOP PRESS: the IPKat has just received the response of the Intellectual Property Lawyers' Association (IPLA) to the same Inquiry.  You can read the IPLA response here.